{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05760300",
            "orgStudyIdInfo": {
                "id": "GS-US-589-6160"
            },
            "secondaryIdInfos": [
                {
                    "id": "2022-502054-13-00",
                    "type": "OTHER",
                    "domain": "European Medicines Agency"
                }
            ],
            "organization": {
                "fullName": "Gilead Sciences",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function",
            "officialTitle": "A Phase 1 Open-Label, Parallel-Design, Multiple-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Bulevirtide in Participants With Normal and Impaired Renal Function",
            "therapeuticArea": [
                "Gastroenterology"
            ],
            "study": "a-multiple-dose-study-of-bulevirtide-in-participants-with-normal-and-impaired-renal-function"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-03-15",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-05",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-05",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-02-27",
            "studyFirstSubmitQcDate": "2023-02-27",
            "studyFirstPostDateStruct": {
                "date": "2023-03-08",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-22",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-23",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Gilead Sciences",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The goals of this study are to compare the amount of study drug, bulevirtide (BLV), that gets into the bloodstream and how long it takes for the body to eliminate it, measure the effect of BLV on bile acids, and evaluate the safety and tolerability of multiple doses of BLV in participants with normal or impaired renal (kidney) function."
        },
        "conditionsModule": {
            "conditions": [
                "Chronic Hepatitis D Infection"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 80,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Group A: Bulevirtide (BLV), Severe Renal Impaired Participants",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with severe renal impairment will receive BLV 2 mg once daily for 6 days.\n\nFollowing completion and evaluation of pharmacokinetics (PK) and safety data from all participants in Group A, additional participant groups (Groups B, C, and D) and BLV doses (2 mg or 10 mg) may be initiated.",
                    "interventionNames": [
                        "Drug: Bulevirtide (BLV)"
                    ]
                },
                {
                    "label": "Group A: BLV, Normal Renal Function (Matched Control Participants)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with normal renal function will receive BLV 2 mg once daily for 6 days.\n\nFollowing completion and evaluation of PK and safety data from all participants in Group A, additional participant groups (Groups B, C, and D) and BLV doses (2 mg or 10 mg) may be initiated.",
                    "interventionNames": [
                        "Drug: Bulevirtide (BLV)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Bulevirtide (BLV)",
                    "description": "Administered via subcutaneous (SC) injections",
                    "armGroupLabels": [
                        "Group A: BLV, Normal Renal Function (Matched Control Participants)",
                        "Group A: Bulevirtide (BLV), Severe Renal Impaired Participants"
                    ],
                    "otherNames": [
                        "Hepcludex\u00ae",
                        "Myrcludex B"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Pharmacokinetic (PK) Parameter: AUCtau of Bulevirtide (BLV)",
                    "description": "AUCtau is defined as area under the concentration versus time curve over the dosing interval at steady state.",
                    "timeFrame": "Day 6: Predose up to 24 hours postdose"
                },
                {
                    "measure": "PK Parameter: Cmax ss of BLV",
                    "description": "Cmax is defined as the maximum observed concentration of drug at steady state.",
                    "timeFrame": "Day 6: Predose up to 24 hours postdose"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "PK Parameter: AUC0-24 of BLV",
                    "description": "AUC0-24 is defined as the concentration of drug over time between time 0 hour and time 24 hours.",
                    "timeFrame": "Day 1: Predose up to 24 hours postdose"
                },
                {
                    "measure": "PK Parameter: Cmax of BLV",
                    "description": "Cmax is defined as the maximum observed concentration of drug.",
                    "timeFrame": "Day 1: Predose up to 24 hours postdose"
                },
                {
                    "measure": "PK Parameter: Tmax of BLV",
                    "description": "Tmax is defined as the time (observed time point) of Cmax.",
                    "timeFrame": "Day 1 and Day 6: Predose up to 24 hours postdose"
                },
                {
                    "measure": "PK Parameter: t1/2 of BLV",
                    "description": "t1/2 is defined as the estimate of the terminal elimination half-life of the drug.",
                    "timeFrame": "Day 1: Predose up to 24 hours postdose and Day 6: Predose up to 48 hours postdose"
                },
                {
                    "measure": "PK Parameter: CLss/F of BLV",
                    "description": "CLss/F is defined as the apparent clearance at steady state.",
                    "timeFrame": "Day 6: Predose up to 48 hours postdose"
                },
                {
                    "measure": "PK Parameter: Vss/F of BLV",
                    "description": "Vss/F is defined as the apparent volume of distribution at steady state.",
                    "timeFrame": "Day 6: Predose up to 48 hours postdose"
                },
                {
                    "measure": "PK Parameter: Ctrough of Total Bile Acids (BA)",
                    "description": "Ctrough is defined as the concentration of total BA at the end of the dosing interval.",
                    "timeFrame": "Day 2 and Day 5 (predose), Day 7, and Day 8"
                },
                {
                    "measure": "PK Parameter: Cmax of Total BA",
                    "description": "Cmax is defined as the maximum observed concentration of total BA.",
                    "timeFrame": "Day 1 and Day 6: Predose up to 24 hours postdose"
                },
                {
                    "measure": "PK Parameter: AUC0-24 of Total BA",
                    "description": "AUC0-24 is defined as the concentration of total BA over time between time 0 hour and time 24 hours.",
                    "timeFrame": "Day 1 and Day 6: Predose up to 24 hours postdose"
                },
                {
                    "measure": "PK Parameter: Tmax of Total BA",
                    "description": "Tmax is defined as the time (observed time point) of Cmax of total BA.",
                    "timeFrame": "Day 1 and Day 6: Predose up to 24 hours postdose"
                },
                {
                    "measure": "Percentage of Participants With Treatment-Emergent Adverse Events",
                    "timeFrame": "First dose date up to 6 days plus 7 days"
                },
                {
                    "measure": "Percentage of Participants With Laboratory Abnormalities",
                    "timeFrame": "First dose date up to 6 days plus 7 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\nAll Individuals:\n\n* Body mass index (BMI) of at least \u2265 18.0 kg/m\\^2 and \u2264 40.0 kg/m\\^2 at screening.\n* No clinically significant abnormalities on electrocardiogram (ECG)\n* No known Liver Disease (Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT)) \u2264 3 x upper limit of normal (ULN) at screening.\n\nIndividuals with Renal Impairment (RI):\n\n* Have RI classification at screening that has been unchanged during the 90 days prior to study drug dosing.\n* Estimated Glomerular Filtration Rate (eGFR) must be the following (using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (Inker 2021)) based on serum creatinine as measured at the screening evaluation:\n\n  * Severe RI (Groups A and B): eGFR \u2265 15 to \u2264 29 mL/min/1.73 m\\^2\n  * Moderate RI (Group C): eGFR \u2265 30 to \u2264 59 mL/min/1.73 m\\^2\n  * Mild RI (Group D): eGFR \u2265 60 to \u2264 89 mL/min/1.73 m\\^2\n* Hemoglobin \u2265 9 g/dL at screening.\n* Individuals with cardiovascular disease, hypertension, diabetes mellitus, hyperlipidemia, hypothyroidism, osteoporosis, and many others) may be included provided that these diseases/conditions are clinically stable.\n\nMatched Control Individuals:\n\n* Have an eGFR of at least 90 mL/min/1.73 m\\^2 (using the CKD-EPI equation) based on serum creatinine as measured at screening evaluation.\n* Matched for sex, age (\u00b1 10 years), and BMI (\u00b1 20%, 18.0 \u2264 BMI \u2264 40.0 kg/m\\^2) with the respective participant in the RI group.\n\nKey Exclusion Criteria:\n\nAll Individuals:\n\n* Positive human immunodeficiency virus (HIV) test, hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibody with detectable HCV viral ribonucleic acid (RNA) at screening.\n* Have any serious or active medical or psychiatric illness (including depression) that, in the opinion of the investigator, would interfere with participant treatment, assessment, or compliance with the protocol.\n\nIndividuals with RI:\n\n* Recent history of reception of any blood or blood products or history of major bleeding within 4 weeks of dosing.\n* Positive test for drugs of abuse, including alcohol at screening or admission, with the exception of opioids and tetrahydrocannabinol (THC, marijuana) under prescription and verified by the investigator as for pain management.\n* Received treatment with trimethoprim or cimetidine or tenofovir prodrugs (tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF)) (affects elimination of creatinine) or with competitors of renal tubular excretion (eg, probenecid, chronic high-dose nonsteroidal anti-inflammatory drugs) within 28 days of Day -1.\n* Received known nephrotoxic drugs (eg, aminoglycosides, amphotericin B, vancomycin, cidofovir, foscarnet, cisplatin, pentamidine, cyclosporine, tacrolimus, herbal remedies (eg, compounds with aristolochic acid)) within 28 days of Day -1.\n* Individuals requiring or anticipated to require dialysis within 90 days of study entry.\n* Serum albumin concentration \\<25 g/L.\n* Uncontrolled treated/untreated hypertension (defined as a mean of 3 repeated measurements for systolic blood pressure \u2265180 mmHg and/or diastolic blood pressure \u2265110 mmHg); current or documented history of repeated clinically significant hypotension or severe episodes of orthostatic hypotension (systolic blood pressure \\<90 mmHg and/or diastolic blood pressure \\<50 mmHg).\n\nMatched Control Individuals:\n\n* Have taken any prescription medications or over-the-counter medications, including herbal products, within 28 days prior to start of study drug dosing, with the exception of vitamins\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "79 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Gilead Clinical Study Information Center",
                    "role": "CONTACT",
                    "phone": "1-833-445-3230 (GILEAD-0)",
                    "email": "GileadClinicalTrials@gilead.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Gilead Study Director",
                    "affiliation": "Gilead Sciences",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Velocity Clinical Research, New Smyrna Beach",
                    "status": "RECRUITING",
                    "city": "Edgewater",
                    "state": "Florida",
                    "zip": "32132",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 28.98888,
                        "lon": -80.90228
                    }
                },
                {
                    "facility": "Panax Clinical Research",
                    "status": "RECRUITING",
                    "city": "Miami Lakes",
                    "state": "Florida",
                    "zip": "33014",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 25.90871,
                        "lon": -80.30866
                    }
                },
                {
                    "facility": "Floridian Clinical Research, LLC",
                    "status": "RECRUITING",
                    "city": "Miami Lakes",
                    "state": "Florida",
                    "zip": "33016",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 25.90871,
                        "lon": -80.30866
                    }
                },
                {
                    "facility": "Clinical Pharmacology of Miami, LLC",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33014",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "Advanced Pharma CR, LLC",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33147",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "Global Clinical Professionals Research",
                    "status": "RECRUITING",
                    "city": "Saint Petersburg",
                    "state": "Florida",
                    "zip": "33705",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 27.77086,
                        "lon": -82.67927
                    }
                },
                {
                    "facility": "Genesis Clinical Research, LLC",
                    "status": "RECRUITING",
                    "city": "Tampa",
                    "state": "Florida",
                    "zip": "33603",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 27.94752,
                        "lon": -82.45843
                    }
                },
                {
                    "facility": "Massachusetts General Hospital - Renal Associates Clinic",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Nucleus Network",
                    "status": "RECRUITING",
                    "city": "Saint Paul",
                    "state": "Minnesota",
                    "zip": "55114",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 44.94441,
                        "lon": -93.09327
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Gilead Clinical Trials Website",
                    "url": "https://www.gileadclinicaltrials.com/study?nctid=NCT05760300"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003699",
                    "term": "Hepatitis D"
                },
                {
                    "id": "D000019701",
                    "term": "Hepatitis D, Chronic"
                },
                {
                    "id": "D000051437",
                    "term": "Renal Insufficiency"
                }
            ],
            "ancestors": [
                {
                    "id": "D000006505",
                    "term": "Hepatitis"
                },
                {
                    "id": "D000008107",
                    "term": "Liver Diseases"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000006521",
                    "term": "Hepatitis, Chronic"
                },
                {
                    "id": "D000002908",
                    "term": "Chronic Disease"
                },
                {
                    "id": "D000020969",
                    "term": "Disease Attributes"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000007674",
                    "term": "Kidney Diseases"
                },
                {
                    "id": "D000014570",
                    "term": "Urologic Diseases"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                },
                {
                    "id": "D000006525",
                    "term": "Hepatitis, Viral, Human"
                },
                {
                    "id": "D000014777",
                    "term": "Virus Diseases"
                },
                {
                    "id": "D000007239",
                    "term": "Infections"
                },
                {
                    "id": "D000012327",
                    "term": "RNA Virus Infections"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M26718",
                    "name": "Renal Insufficiency",
                    "asFound": "Impaired Renal Function",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9592",
                    "name": "Hepatitis A",
                    "relevance": "LOW"
                },
                {
                    "id": "M9591",
                    "name": "Hepatitis",
                    "relevance": "LOW"
                },
                {
                    "id": "M10283",
                    "name": "Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M6368",
                    "name": "Communicable Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6899",
                    "name": "Hepatitis D",
                    "asFound": "Hepatitis D",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21616",
                    "name": "Hepatitis D, Chronic",
                    "asFound": "Chronic Hepatitis D",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9607",
                    "name": "Hepatitis, Chronic",
                    "relevance": "LOW"
                },
                {
                    "id": "M11107",
                    "name": "Liver Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6147",
                    "name": "Chronic Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "M22700",
                    "name": "Disease Attributes",
                    "relevance": "LOW"
                },
                {
                    "id": "M10698",
                    "name": "Kidney Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17319",
                    "name": "Urologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9610",
                    "name": "Hepatitis, Viral, Human",
                    "relevance": "LOW"
                },
                {
                    "id": "M17522",
                    "name": "Virus Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15149",
                    "name": "RNA Virus Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "T2726",
                    "name": "Hepatitis D",
                    "asFound": "Hepatitis D",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}